Disease · MONDO_0020642

polycystic kidney disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. polycystic kidney disease. Diseases, record MONDO_0020642. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020642

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: polycystic kidney disease; Open Targets
Open Targets ID: MONDO_0020642; Open Targets
Other names: PKD - polycystic kidney disease, fibrocystic renal disease; Open Targets
Disease Ontology: DOID:0080322; Disease Ontology
MeSH: D007690; MeSH
NCI Thesaurus: C75464; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 7 drugs, from DailyMed and PMDA; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TOLVAPTAN	CHEMBL344159	Small molecule	Approval	DailyMed and PMDA	2	0	0	Drugs and targets
OCTREOTIDE	CHEMBL1680	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CILNIDIPINE	CHEMBL452076	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IMIDAPRIL	CHEMBL317094	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TESEVATINIB	CHEMBL3544983	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
HYDRALAZINE	CHEMBL276832	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
LANREOTIDE	CHEMBL1201185	Protein	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets14

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SSTR2	Somatostatin receptor	2	Somatostatin receptor 2 agonist; Somatostatin receptor agonist	Phase 2/3	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR5	Somatostatin receptor	2	Somatostatin receptor 5 agonist; Somatostatin receptor agonist	Phase 2/3	https://conductscience.org/library/genes/6755	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Phase 2	https://conductscience.org/library/genes/1636	Drugs and targets
AVPR2	Vasopressin V2 receptor	1	Vasopressin V2 receptor antagonist	Approval	https://conductscience.org/library/genes/554	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 2	https://conductscience.org/library/genes/779	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
EPHB4	Ephrin type-B receptor 4	1	Ephrin type-B receptor 4 inhibitor	Phase 2	https://conductscience.org/library/genes/2050	Drugs and targets

1 to 10 of 14

See all 14 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00426153	Octreotide in Severe Polycystic Liver Disease	Phase 2/3	42	2012-11-21	Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain	OCTREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT00890279	Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)	Phase 2	160		Kidney, Polycystic, Autosomal Dominant	CILNIDIPINE, IMIDAPRIL	Its record names the disease	ClinicalTrials.gov
NCT01354405	Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)		43		Polycystic Liver Disease	LANREOTIDE	Its record names the disease	ClinicalTrials.gov
NCT03423810	Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients	Early phase 1	14		Polycystic Kidney Diseases	HYDRALAZINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Octreotide vs Placebo: serious adverse events	3 of 28	0 of 14	42	NCT00426153

Source Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22773240	RESULT	1	PubMed
39356039	DERIVED	1	PubMed
26166166	DERIVED	1	PubMed
25369108	DERIVED	1	PubMed
22475206	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020642

GET https://conductscience.org/api/diseases/v1/MONDO_0020642/drugs

API reference For AI assistants